Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Galapagos (GLPG) Share Price
Media stories about Galapagos (NASDAQ:GLPG) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galapagos earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.2705765474859 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities analysts have recently weighed in on the company. BidaskClub cut Galapagos from a “buy” rating to a “hold” rating in a research report on Friday, March 2nd. ValuEngine upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $118.00 price target on shares of Galapagos in a research report on Monday, November 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $111.00.
Galapagos (GLPG) traded up $0.30 during trading on Wednesday, reaching $103.66. The company had a trading volume of 46,259 shares, compared to its average volume of 102,442. Galapagos has a twelve month low of $72.90 and a twelve month high of $121.09. The stock has a market capitalization of $5,260.00, a PE ratio of -38.86 and a beta of 0.99.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.